var data={"title":"Sevelamer: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sevelamer: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6948?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sevelamer-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sevelamer: Patient drug information&quot;</a> and <a href=\"topic.htm?path=sevelamer-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sevelamer: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220777\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Renagel;</li>\n      <li>Renvela</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220778\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Renagel;</li>\n      <li>Renvela</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220795\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Phosphate Binder</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220780\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>The dosing of sevelamer carbonate and sevelamer hydrochloride are similar; when switching from one product to another, the same dose (on a mg per mg basis) should be utilized.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Control of serum phosphorous:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patients not taking a phosphate binder: Initial: 800 to 1,600 mg 3 times daily with meals; the initial dose may be based on serum phosphorous levels:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;5.5 mg/dL to &lt;7.5 mg/dL: 800 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;7.5 mg/dL to &lt;9 mg/dL: 1,200 to 1,600 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;9 mg/dL: 1,600 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maintenance dose adjustment based on serum phosphorous concentration (goal range of 3.5 to 5.5 mg/dL; maximum dose studied was equivalent to 13 g/day [sevelamer hydrochloride] or 14 g/day [sevelamer carbonate]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;5.5 mg/dL: Increase by 400 to 800 mg per meal at 2-week intervals</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">3.5 to 5.5 mg/dL: Maintain current dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;3.5 mg/dL: Decrease by 400 to 800 mg per meal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Dosage adjustment when switching between phosphate-binder products:</i> 667 mg of calcium acetate is equivalent to ~800 mg sevelamer (carbonate or hydrochloride)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conversion based on dose per meal:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Calcium acetate 667 mg: Convert to 800 mg Renagel/Renvela</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Calcium acetate 1,334 mg: Convert to 1,600 mg as Renagel/Renvela (800 mg tablets x 2) <b>or</b> 1,200 mg as Renagel (400 mg tablets x 3)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Calcium acetate 2,001 mg: Convert to 2,400 mg as Renagel/Renvela (800 mg tablets x 3) <b>or</b> 2,000 mg as Renagel (400 mg tablets x 5)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5265838\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=sevelamer-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sevelamer: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Control of serum phosphorous:</b> Sevelamer carbonate (Renvela): Children &ge;6 years and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patients not taking a phosphate binder: Initial: 800 to 1,600 mg 3 times daily with meals; dose based on body surface area:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">BSA &ge;0.75 to &lt;1.2 m<sup>2</sup>: 800 mg per meal; titrate as needed by 400 mg per dose at 2 week intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">BSA &ge;1.2 m<sup>2</sup>: 1,600 mg per meal; titrate as needed by 800 mg per dose at 2 week intervals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220781\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22553631\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22553632\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220760\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral, as carbonate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renvela: 0.8 g (1 ea, 90 ea); 2.4 g (1 ea, 90 ea) [citrus flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.8 g (1 ea, 90 ea); 2.4 g (1 ea, 90 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as carbonate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renvela: 800 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 800 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renagel: 400 mg [DSC], 800 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220745\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220762\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with meals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for oral suspension: May prepare an oral suspension in water using the directed amount of water appropriate for the packet size <b>or</b> may premix the entire content of the packet with a small amount of food or beverage (do not heat or add to heated foods or liquids).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Preparations should be consumed immediately or within 30 minutes. Oral suspension in water may need to be resuspended immediately before drinking.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Swallow whole; do not crush, chew, or break.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220761\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Control of serum phosphorous:</b> Control of serum phosphorous in patients with chronic kidney disease on hemodialysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220802\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renagel may be confused with Reglan, Regonol, Renvela </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renvela may be confused with Reglan, Regonol, Renagel</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sevelamer may be confused with Savella</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Renagel [US, Canada, and multiple international markets] may be confused with Remegel brand name for aluminium hydroxide and magnesium carbonate [Netherlands] and for calcium carbonate [Hungary, Great Britain and Ireland] and with Remegel Wind Relief brand name for calcium carbonate and simethicone [Great Britain]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220752\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Metabolic acidosis (children: 34% [Pieper 2006]); adults: Frequency not defined)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (22%), nausea (20%), diarrhea (19%), dyspepsia (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypercalcemia (5% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (9%), constipation (8%), flatulence (8%), peritonitis (peritoneal dialysis: 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Fecal impaction, hypersensitivity reaction, intestinal obstruction (rare), intestinal perforation (rare), pruritus, skin rash</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220765\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to sevelamer or any component of the formulation; bowel obstruction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypophosphatemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220749\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal effects: Bowel obstruction and perforation have been reported. Dysphagia and esophageal tablet retention have also been reported with the tablet formulation; consider change to suspension formulation in patients with a history of swallowing disorders</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal disease: Use with caution in patients with gastrointestinal disorders including dysphagia, swallowing disorders, severe gastrointestinal motility disorders (including severe constipation), or major gastrointestinal surgery. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions for more detailed information</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vitamins: May cause reductions in vitamin D, E, K, or folic acid absorption. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tablets: Should not be taken apart or chewed; broken or crushed tablets will rapidly expand in water/saliva and may be a choking hazard.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300038\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220754\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10261&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Calcitriol (Systemic): Sevelamer may decrease the serum concentration of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholic Acid: Sevelamer may decrease the absorption of Cholic Acid.  Management: Administer cholic acid at least 1 hour before or 4 to 6 hours after administration of any bile acid-binding products, such as sevelamer, to minimize the potential for a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Sevelamer may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levothyroxine: Sevelamer may decrease the serum concentration of Levothyroxine.  Management: Consider separating administration of sevelamer and levothyroxine by at least several hours whenever possible in order to decrease the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Sevelamer may decrease the serum concentration of Mycophenolate.  Management: Administer mycophenolate at least 2 hours prior to sevelamer administration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Sevelamer may decrease the absorption of Quinolones.  Management: Administer oral quinolones at least 2 hours before or 6 hours after sevelamer.<b> Exceptions: </b>LevoFLOXacin (Oral Inhalation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Sevelamer may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13851538\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">May cause reductions in vitamin D, E, K, or folic acid absorption. Management: Must be administered with meals. Consider vitamin supplementation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220756\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220768\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Sevelamer is not absorbed systemically; however, it may cause a reduction in the absorption of fat soluble vitamins and folic acid.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220769\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Sevelamer is not absorbed systemically; however, it may cause a reduction in the absorption of fat soluble vitamins and folic acid.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1044875\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Take with meals. Reduced levels of folic acid, and vitamins D, E, and K may occur; most hemodialysis patients in clinical trials received vitamin supplementation. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220758\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum chemistries, including bicarbonate and chloride</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum calcium and phosphorus: Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progression of CKD, and the use of treatments for CKD-mineral and bone disorders (KDIGO, 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD stage 3: Every 6-12 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD stage 4: Every 3-6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD stage 5 and 5D: Every 1-3 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Periodic 24-hour urinary calcium and phosphorus; magnesium; alkaline phosphatase every 12 months or more frequently in the presence of elevated PTH; creatinine, BUN, albumin; intact parathyroid hormone (iPTH) every 3-12 months depending on CKD severity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13203338\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corrected total serum calcium (K/DOQI, 2003): CKD stages 3 and 4: 8.4-10.2 mg/dL (2.1-2.6 mmol/L); CKD stage 5: 8.4-9.5 mg/dL (2.1-2.37 mmol/L); KDIGO guidelines recommend maintaining normal ranges for all stages of CKD (3-5D) (KDIGO 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphorus (K/DOQI, 2003):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD stages 3 and 4: 2.7-4.6 mg/dL (0.87-1.48 mmol/L) (adults); maintain within age-appropriate limits (children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD stage 5 (including those treated with dialysis): 3.5-5.5 mg/dL (1.13-1.78 mmol/L) (children &gt;12 years and adults); 4-6 mg/dL (1.29-1.94 mmol/L) (children 1-12 years)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">KDIGO guidelines recommend maintaining normal ranges for CKD stages 3-5 and lowering elevated phosphorus levels toward the normal range for CKD stage 5D (KDIGO, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum calcium-phosphorus product (K/DOQI, 2003): CKD stage 3-5: &lt;55 mg<sup>2</sup>/dL<sup>2</sup> (children &gt;12 years and adults); &lt;65 mg2/dL2 (children &le;12 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PTH: Whole molecule, immunochemiluminometric assay (ICMA): 1.0-5.2 pmol/L; whole molecule, radioimmunoassay (RIA): 10.0-65.0 pg/mL; whole molecule, immunoradiometric, double antibody (IRMA): 1.0-6.0 pmol/L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Target ranges by stage of chronic kidney disease (KDIGO, 2009): CKD stage 3-5: Optimal iPTH is unknown; maintain normal range (assay-dependent); CKD stage 5D: Maintain iPTH within 2-9 times the upper limit of normal for the assay used</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220748\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Sevelamer (a polymeric compound) binds phosphate within the intestinal lumen, limiting absorption and decreasing serum phosphate concentrations without altering calcium, aluminum, or bicarbonate concentrations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220764\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Reduction in serum phosphorus has been demonstrated after 1-2 weeks (Burke 1997; Chertow 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Not systemically absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220767\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Renvela Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.8 g (1): $20.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.4 g (1): $20.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Sevelamer Carbonate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.8 g (1): $11.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.4 g (1): $11.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Renagel Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (180): $1,524.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Renvela Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (270): $1,828.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sevelamer Carbonate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (270): $1,021.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038827\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Inophos (BD);</li>\n      <li>Invela (KR);</li>\n      <li>Postiline (AR);</li>\n      <li>Renagel (AE, AT, AU, BB, BR, CR, CY, DO, ES, FI, GR, GT, HN, HR, IE, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, NI, PA, PE, PL, PT, QA, RO, SA, SI, SK, SV, TR, TW, UY);</li>\n      <li>Renosev (BD);</li>\n      <li>Renvela (AE, AT, BB, BE, CH, CL, CN, CR, CY, CZ, DE, DK, DO, EE, ES, FR, GB, GT, HK, HN, HR, ID, IE, IL, IS, KR, KW, LB, LT, LU, LV, MT, MY, NI, NL, NO, PA, PH, PL, PT, RO, SA, SE, SG, SI, SK, SV, TH, TR);</li>\n      <li>Sevel (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Burke SK, Slatopolsky EA, and Goldberg DI, &quot;RenaGel, a Novel Calcium- and Aluminium-Free Phosphate Binder, Inhibits Phosphate Absorption in Normal Volunteers,&quot; <i>Nephrol Dial Transplant</i>, 1997, 12(8):1640-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevelamer-drug-information/abstract-text/9269642/pubmed\" target=\"_blank\" id=\"9269642\">9269642</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chertow GM, Burke SK, Lazarus JM, et al, &quot;Poly[allylamine Hydrochloride] (RenaGel): A Noncalcemic Phosphate Binder for the Treatment of Hyperphosphatemia in Chronic Renal Failure,&quot; <i>Am J Kidney Dis</i>, 1997, 29(1):66-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevelamer-drug-information/abstract-text/9002531/pubmed\" target=\"_blank\" id=\"9002531\">9002531</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Delmez J, Block G, Robertson J, et al, &ldquo;A Randomized, Double-Blind, Crossover Design Study of Sevelamer Hydrochloride and Sevelamer Carbonate in Patients on Hemodialysis,&rdquo; <i>Clin Nephrol</i>, 2007, 68(6):386-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevelamer-drug-information/abstract-text/18184521/pubmed\" target=\"_blank\" id=\"18184521\">18184521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 13. Treatment of Bone Disease in Chronic Kidney Disease.&quot; Available at https://www.kidney.org/sites/default/files/docs/boneguidelines.pdfhttps://www.kidney.org/sites/default/files/docs/boneguidelines.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease,&quot; 2002. Available at https://www.kidney.org/sites/default/files/docs/ckd_evaluation_classification_stratification.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, &quot;KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD),&quot; <i>Kidney Int Suppl</i>, 2009, 76(S113):1-130.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevelamer-drug-information/abstract-text/19644521/pubmed\" target=\"_blank\" id=\"19644521\">19644521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahdavi H, Kuizon BD, Gales B, et al, &ldquo;Sevelamer Hydrochloride: An Effective Phosphate Binder in Dialyzed Children,&rdquo; <i>Pediatr Nephrol</i>, 2003, 18(12):1260-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevelamer-drug-information/abstract-text/14586677/pubmed\" target=\"_blank\" id=\"14586677\">14586677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pieper AK, Haffner D, Hoppe B, et al, &ldquo;A Randomized Crossover Trial Comparing Sevelamer With Calcium Acetate in Children With CKD,&rdquo; <i>Am J Kid Dis</i>, 2006, 47(4):625-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevelamer-drug-information/abstract-text/16564940/pubmed\" target=\"_blank\" id=\"16564940\">16564940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Renagel (sevelamer hydrochloride) [prescribing information]. Cambridge, MA: Genzyme Corp; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Renagel (sevelamer hydrochloride) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Renvela (sevelamer carbonate) [prescribing information]. Cambridge, MA: Genzyme Corp; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Renvela (sevelamer carbonate) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Storms LE, Chicella MF, and Dice JE, &ldquo;Sevelamer Therapy for Pediatric End-Stage Renal Disease,&rdquo; <i>Pharmacotherapy</i>, 2006, 26(3):410-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevelamer-drug-information/abstract-text/16503722/pubmed\" target=\"_blank\" id=\"16503722\">16503722</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10261 Version 145.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F220777\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F220778\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F220795\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F220780\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F5265838\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F220781\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22553631\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22553632\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F220760\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F220745\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F220762\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F220761\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F220802\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F220752\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F220765\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F220749\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300038\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F220754\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F13851538\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F220756\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F220768\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F220769\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F1044875\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F220758\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F13203338\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F220748\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F220764\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F220767\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038827\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10261|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sevelamer-patient-drug-information\" class=\"drug drug_patient\">Sevelamer: Patient drug information</a></li><li><a href=\"topic.htm?path=sevelamer-pediatric-drug-information\" class=\"drug drug_pediatric\">Sevelamer: Pediatric drug information</a></li></ul></div></div>","javascript":null}